DENVER, Aug. 27 /PRNewswire/ -- Myogen, Inc., a biopharmaceutical company
focused on discovering, developing and commercializing drugs for the treatment
of cardiovascular diseases, announced today the closing of a $40 million
private placement of additional shares of its Series D Preferred Stock to a
group of current institutional investors led by New Enterprise Associates.
Other investors included JPMorgan Partners, InterWest Partners, Sequel Venture
Partners, Perseus-Soros Biopharmaceutical Fund, CMEA Ventures, and Pacific Rim
Ventures.
About Myogen
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular diseases. The Company's academic founders, staff
and collaborators have made significant contributions to defining the
molecular bases of cardiovascular disease and improving its treatment. The
Company believes that its expertise enables it to discover and develop
therapies that address underlying mechanisms of cardiovascular disease,
evaluate and in-license product candidates and guide our clinical development
efforts. Myogen currently markets one product in Europe for the treatment of
acute decompensated heart failure and is developing three product candidates
for three distinct cardiovascular indications. Myogen occupies 22,000 square
feet of laboratory and office space in the Denver, Colorado area and currently
has approximately 50 employees. Please visit our website at http://www.myogen.com .
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Joseph L. Turner, Chief Financial Officer,
+1-303-464-5222, joe.turner@myogen.com, or Derek K. Cole,
Director, Investor Relations, +1-303-464-3986,
derek.cole@myogen.com, for Myogen, Inc.
|
